Benzyl isothiocyanate (BITC) is a dietary chemopreventive agent that inhibits the growth of various human cancer cells by causing apoptotic cell death. In this study, we demonstrate that BITC not only induces apoptosis but also induces autophagy in human hormone-sensitive (Rv1) and -refractory (PC3) prostate cancer cells. In BITC-treated cells, the induction of autophagy was detected by monitoring the processing of an autophagy marker protein, microtubule-associated protein 1 light chain 3 (LC3), the aggregation of LC3 into granular structures and the formation of acidic organelles. Inhibition of autophagy using 3-methyladenine increased BITC-induced apoptosis, whereas the administration of caspase inhibitor suppressed BITC-induced cell death. Our data also showed that BITC inhibits mammalian target of rapamycin (mTOR) kinase activity in a dose-dependent manner. The expression of phospho-mTOR (Ser2481), an indicator of mTOR intrinsic catalytic activity, and phospho-UNC-51-like kinase 1 (Ser757), a direct substrate of mTOR, were decreased in BITC-treated cells. However, the increased expression of phospho-mTOR (Ser2448), phospho-AKT (Ser473) and antiapoptotic Bcl-2 were detected only in PC3 cells at later stages of BITC treatment. Collectively, our results show that BITC induces a protective autophagy response in Rv1 and PC3 cells through inhibition of the mTOR signaling pathway. Activation of the AKT survival pathway was only observed in PC3 cells, representing a resistance mechanism of advanced prostate cancer upon BITC treatment. These findings could potentially contribute to the beneficial effect of BITC in prostate cancer treatments.
Introduction
Prostate cancer is among the most prevalent cancers in men worldwide and the leading cause of cancer-related deaths in American men (1, 2) . Despite long-term efforts to develop targeted therapies, the current effective treatment for hormone-sensitive prostate cancer mainly relies on hormonal therapy with luteinizing hormone-releasing hormone agonists and antiandrogens (3) . In advanced prostate cancers that are hormone resistant and metastatic, the only option is chemotherapy with docetaxel (4) . Because the risk factors of prostate carcinogenesis are complex (age, environmental toxicity and genetic background), novel approaches and agents for prevention and treatment are necessary to reduce morbidity and mortality. Hence, more researchers are reporting the possibility of using natural products as chemopreventive candidates by inducing apoptotic cell death in cancer cells, including prostate cancer cells (5) (6) (7) (8) (9) (10) .
Epidemiological studies show that the dietary intake of certain fruits and vegetables, including cruciferous vegetables, reduces the risk of many cancers, including prostate cancers (11) (12) (13) (14) (15) . The anticancer effects of cruciferous vegetables have been attributed to chemicals with an isothiocyanate (ITC) functional group. These organic ITCs are released upon the processing of these vegetables (15) . Benzyl isothiocyanate (BITC) is one such compound that has been reported to induce apoptosis in human breast (16) (17) (18) (19) , ovarian (20) , pancreatic (21, 22) and osteogenic (23) cancer cells and to inhibit migration and invasion in gastric (24) and colon cancer (25) cells. In prostate cancer cells, BITC induces Bcl-xL phosphorylation with simultaneous cell cycle arrest and subsequent apoptosis (26) . Recently, a report on the effect of phenethyl isothiocyanate, another member of the cruciferous vegetable-derived ITCs, revealed the ability of phenethyl isothiocyanate to reduce the viability of prostate cancer cells in culture by causing apoptotic and autophagic cell death (27) .
Autophagy (self-eating) is a natural mechanism of sequestration and degradation of intracellular organelles in lysosomes when cells undergo stress, such as nutrition deprivation. Several anticancer agents were reported to induce autophagy and either protect or further sensitize cells to drug treatment (28) . Furthermore, autophagy is now considered a therapeutic target in cancer cells that are resistant to anticancer drugs (29) . Previous studies from our laboratory have shown that zoledronic acid (ZA), which induces apoptotic cell death in prostate cancer cells, also induces autophagic cell death (30) . Only the simultaneous inhibition of apoptosis and autophagy could rescue ZA-induced cell death, suggesting that the autophagy induced by ZA does not represent a protective effect on prostate cancer cells as has been reported for prostate cancer cells treated with sulforaphane, another ITC (31) . In this study, we investigated the effect of BITC on the induction of autophagic responses in prostate cancer cells. We document, for the first time, that the chemopreventive agent BITC induces protective autophagy in hormone-sensitive and -refractory prostate cancer cells through the inhibition of the mammalian target of rapamycin (mTOR) signaling pathway.
BITC induces protective autophagy by mTOR inhibition
Detection of apoptosis BITC-induced apoptosis was assessed by flow cytometry analysis of subdiploid (sub-G 0 /G 1 ) cells and the activation of caspase 3/7 activity. After BITC treatment, one million cells were fixed in 70% ethanol at 4°C overnight. Cells were then washed with ice-cold phosphate-buffered saline twice, pelleted and resuspended in 0.04 mg/ml propidium iodide (PI) and 100 mg/ml ribonuclease in phosphate-buffered saline. The DNA content per cell was determined using a FACSCalibur flow cytometer, and the data were analyzed with CellQuest Pro software (Becton Dickinson, San Jose, CA). Activation of caspase 3/7 was assayed using (Z-DEVD) 2 -R110 substrate (Bachem, Torrance, CA) as described (32) . Briefly, cells were plated in 96-well plates and allowed to attach by overnight incubation. The cells were pretreated 2 h with the indicated inhibitors and then treated with DMSO (control) or the desired concentrations of BITC. Subsequently, the cells were directly lysed by adding caspase 3/7 assay buffer containing (Z-DEVD) 2 -R110 substrate and incubated at 37°C for 1 h. The fluorescent intensity of proteolytically released fluorophore R110 was then measured using a plate reader (Victor X2; PerkinElmer, Waltham, MA) with an excitation of 485 nm and emission of 535 nm.
Detection of autophagy
Immunoblotting and immunofluorescence of LC3. To perform immunoblotting analysis of microtubule-associated protein 1 light chain 3 (LC3), cells subjected to the indicated treatments were harvested and lysed, and the protein concentration was determined by a BCA protein assay (Pierce, Rockford, IL). Proteins were separated by 14% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA) before probing with LC3 antibodies (#AP1802a, MAP1LC3B; Abgent, San Diego, CA). Subsequent immunoblotting procedures were performed using a chemiluminescence procedure (Millipore) as per the manufacturer's instructions. To perform immunofluorescence detection of LC3, cells were seeded in chamber slides (Becton Dickinson) and subjected to the indicated treatments. After removal of the medium, cells were washed twice with phosphate-buffered saline and fixed with ice-cold methanol at −20°C, followed by permeabilization with 0.25% Triton X-100 at 4°C. The primary antibody to LC3 was incubated at 4°C overnight before incubation with the fluorescein isothiocyanate secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA). Analysis was performed using a fluorescence microscope (Olympus, Tokyo, Japan) equipped with the appropriate excitation and emission filters.
Acridine orange staining for autophagy detection. Cells were seeded in sixwell plates and treated with BITC for 24 h before acridine orange (AO) staining as described previously (30) . In the bafilomycin A1 (Baf A1; Santa Cruz Biotechnology, Santa Cruz, CA) cotreatment study, cells were treated with 200 nm Baf A1 for 1 h prior to the addition of AO.
Quantification of acidic vesicular organelles with AO staining using flow cytometry. In AO-stained cells, the acidic compartments fluoresce bright red, and the intensity of the red fluorescence is proportional to the degree of acidity. Therefore, the volume of the cellular acidic compartment can be quantified. Cells were stained with AO for 1 h, removed from the plate with trypson-ethylenediaminetetraacetic acid and collected in phenol red-free medium. Green (510-530 nm) and red (650 nm) fluorescence emission from 1 × 10 5 cells illuminated with blue (488 nm) excitation light was measured with a FACSCalibur using CellQuest software (Becton Dickinson).
mTOR kinase assay. The activity of mTOR was measured with colorimetric K-LISA mTOR activity assay kit (Calbiochem, San Diego, CA). In brief, cells treated with BITC for 24 h were lysed in lysis buffer (50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 50 mM β-glycerophosphate, 10% glycerol, 1% Tween 20, 1 mM ethylenediaminetetraacetic acid, 20 nm microcystin-LR, 25 mM LaF) supplemented with complete protease cocktail inhibitors (Roche Diagnostics). After centrifugation at 16 000g for 20 min to eliminate debris, protein concentration in the lysates was determined by the BCA protein assay (Pierce) and adjusted to 2 mg/ml. mTOR proteins were immunoprecipitated with mTOR antibody and protein A/G-agarose from 0.5 ml of the total protein lysates. A p70S6K-glutathione-S-transferase fusion protein, as a specific mTOR substrate, and adenosine triphosphate were added to the immunoprecipitated complex. After phosphorylation of S6K70 at T389 by the active mTOR in the sample, the supernatant was added to the glutathione-coated wells. The phosphorylated p70S6K was then detected with anti-p70S6K-pT389 antibody, followed by detection with horseradish peroxidase antibody conjugate and tetra-methylbenzidine (TMB) substrate. The mTOR activity was measured in terms of absorbance in microplate reader.
Western blot analysis. The protein levels of cells treated with 20 µM BITC for the indicated periods of time were examined using western blot analysis as described for the immunoblotting for LC3. Antibodies against mTOR, phospho-mTOR (Ser2481), phospho-mTOR (Ser2448), UNC-51-like kinase 1 (ULK1), phospho-ULK1 (Ser757), caspase 3, AKT and phospho-AKT (Ser473) were from Cell Signaling Technology (Beverly, MA). Antibodies against extracellular signal-regulated kinase 1 (ERK1) and phospho-ERK were from Santa Cruz Biotechnology and those against Bcl-2 and β-actin were from Sigma. The intensity of immunoreactive bands was determined using GeneTools software (Syngene, Frederick, MD) after scanning the developed films. Results are expressed as mean ± SD of three independent experiments.
Statistical analysis. All experiments were performed at least in triplicate, and data are expressed as the means ± SD. The statistical significance of the difference in the measured variables between the treatment and control groups was determined by Student's t-test and was considered significant at P < 0.05.
Results

BITC treatment decreased the viability of Rv1 and PC3 cells by inducing apoptosis
The viability of Rv1 and PC3 cells, which represent hormone-sensitive and -refractory prostate cancer cells, respectively, was tested after BITC treatment. BITC significantly inhibited the growth of both Rv1 and PC3 cells in a time-and dose-dependent manner, as shown in Figure 1A 
BITC treatment induced autophagy in prostate cancer cells Elevated levels of the LC3-II protein in Rv1 and PC3 cells treated with BITC.
Several ITCs are known to induce autophagy in several types of cancer cells (33) . We, therefore, sought to determine whether BITC treatment causes induction of autophagy in prostate cancer cells. Processing of the LC3-II protein is characteristic of activation of the autophagy pathway (31) . Total protein lysates from Rv1 and PC3 cells treated with vehicle (−) or 20 µM BITC (+) for 6, 16 and 24 h were assessed for LC3-II formation with an autophagy LC3 antibody that detects both LC3-I and LC3-II (APG8b, N-term; Abgent). As shown in Figure 2A , the LC3-II level was elevated in BITC-treated Rv1 and PC3 cells as early as 6 h and continued accumulating up to 24 h. We further extended the treatment duration from 24 h to 3 days with 10 and 20 µM BITC ( Figure 2B) ; the amount of LC3-II in Rv1 cells increased with the dosage of BITC and incubation time, but its level was even greater in PC3 cells treated with 20 µM BITC.
Aggregation of the LC3 protein into vesicular organelles in cells treated with BITC.
To further analyze autophagosome formation, we detected LC3 localization using cell-based immunofluorescence studies on Rv1 and PC3 cells. In cells treated with 20 µM BITC for 24 h, the LC3 protein increased in total abundance and aggregated in granular/ vesicular structures ( Figure 2C ). Different cell types have been shown to exhibit varying degrees of basal autophagocytosis (28) . Therefore, autophagosomes were quantified in control (DMSO) and BITC-treated cells to determine the fraction of cells exhibiting increased levels of LC3 aggregation, as shown in Figure 2D . The results demonstrated that BITC treatment significantly elevated the cellular abundance of autophagosomes (26.37% versus 1.3% in Rv1 cells and 43.52% versus 0.91% in PC3 cells).
BITC treatment caused the formation of acidic vesicular organelles. Another characteristic of autophagy is the formation of acidic vesicular organelles (AVOs), which can be detected by vital staining using AO (30, 31, 34) . As depicted in Figure 2E and F, vital staining of Rv1 and PC3 cells with AO showed the accumulation of AVOs in the cytoplasm of cells treated with 20 µM BITC (Figure 2, E2 and F2 ). This result further confirmed that the autophagic process was activated by BITC treatment. Baf A1 is a H+ adenosine triphosphatase inhibitor that prevents the transition of autophagosomes to autophagolysosomes by disrupting lysosome fusion (34) . The accumulation of AVOs induced by BITC treatment was markedly reduced with 2 h pretreatment of Baf A1 in BITC-treated cells ( Figure 2, E4 and F4) . Moreover, the Baf A1 treatment also caused the accumulation of LC3-II in BITC-treated cells ( Figure 2G ). Taken together, these results indicate that BITC treatment resulted in the formation of autophagolysosomes via autophagosomes fusion with lysosomes. In order to further confirm that BITC causes autophagy induction, the cells treated with BITC were analyzed for AVOs-positive populations in a concentration-and time-dependent manner. As shown in Figure 2H 
Autophagy inhibited BITC-induced apoptosis
We next raised the question whether induction of autophagy affects BITC-induced apoptosis. 3-MA, a known inhibitor of class III PI3-kinase (31), was employed to address this question. The decreased level of LC3-II was detected in BITC-treated cells with 2 h pretreatment of 1 mM 3-MA ( Figure 3A The caspase 3/7 activities were also higher in the presence of 3-MA compared with BITC treatment alone ( Figure 3E and F) . The data presented above indicate that BITC treatment induces both apoptosis and autophagy, and BITC-induced autophagy inhibits apoptosis in prostate cancer cells. We next evaluated whether the induction of autophagy in BITC-treated cells actually contributes to cell death by cotreating with 3-MA or Z-VAD-FMK to inhibit autophagy or apoptosis, respectively. As shown in Figure 4 , the viability of Rv1 ( Figure 4A ) and PC3 ( Figure 4B ) cells treated with 20 µM BITC for 24 h decreased to 42.86 ± 5.71% and 63.68 ± 2.03% compared with the DMSO-treated controls. Treatment with 1 mM 3-MA or 20 µM Z-VAD-FMK alone slightly decreased and increased, respectively, the viability of both Rv1 and PC3 cells. Cotreatment of BITC with 3-MA decreased cell viability from 42.86 ± 5.71% to 32.05 ± 3.92% and 63.68 ± 2.03% to 50.05 ± 2.02% in Rv1 and PC3 cells, respectively. Cotreatment of BITC with Z-VAD-FMK nearly restored cell viability.
BITC treatment inhibited mTOR signaling in prostate cancer cells
It is now well known that mTOR is a regulator of autophagy in cells under starvation or various other forms of cellular stress (35) . Inhibition of mTOR increases the expression of autophagy-related 
BITC induces protective autophagy by mTOR inhibition
genes (Atgs), such as Atg8 (LC3), and the kinase activity of Atg1 (36) . Both are key components in autophagy. We, therefore, detected mTOR kinase activity in cells treated with different doses of BITC. The mTOR kinase activity was decreased at 24 h post-BITC treatment in a dose-dependent manner. Moreover, the inhibition of kinase activity was more profound in PC3 compared with Rv1 cells (Figure 5A and B) . We next detected the expression of mTOR, phospho-mTOR (Ser 2448 and Ser2481), ULK1, phospho-ULK1 (Ser757) in cells treated with 20 µM of BITC. As shown in Figure 5C and D, a time course study using cell lysates from BITC-treated Rv1 and PC3 cells for 6-72 h showed inhibition of mTOR signaling. BITC treatment slightly increased level of phospho-mTOR (Ser2481), an indicator of mTOR intrinsic catalytic activity, in Rv1 cells at 6 and 12 h, and then the expression started to decline at 24-72 h. In PC3 cells, the expression of phospho-mTOR (Ser2481) was decreased at all time points tested, suggesting the inhibition of mTOR activity upon BITC treatment ( Figure 5E and F) . The expression level ULK1 was decreased in both cells treated with BITC, and the expression 
of phospho-ULK1 (Ser757), a direct substrate of mTOR (37) , was decreased from 6-72 h in Rv1 cells and was increased from 48 h in PC3 cells. Although mTOR inhibition was observed in both cells treated with BITC as judged by the inhibition of mTOR kinase activity and the decreased expression of phospho-mTOR (Ser2481), the inhibition in PC3 seemed to fade after 48 h as phospho-mTOR (Ser2448), which is a substrate of phosphatidylinositol 3 kinase (PI3K)/AKT signaling (38), started to accumulate. Furthermore, the expression of phospho-ULK1 (Ser757) was not correlated well with the expression of phospho-mTOR (Ser2481) in our results. There may be other pathways that interfere with the activation of ULK1 other than mTOR in BITC-treated cells; however, further studies are needed to substantiate this assumption. Another known pathway to induce autophagy is through the activation of ERK 1/2 signaling (28). However, the expression of phospho-ERK1 and phospho-ERK2 (upper and lower band, respectively) showed no difference in BITCtreated cells compared with control ( Figure 5C and D) . These results suggest that BITC induces the inhibition of mTOR signaling and the subsequent induction of autophagy.
BITC treatment activated the AKT pathway in PC3 but not Rv1 cells
BITC exhibited greater cytotoxicity in Rv1 cells compared with PC3 cells, as shown in Figure 1 . Furthermore, inhibition of phosphomTOR (Ser2448) in BITC-treated PC3 cells seemed to be restored in the later stages of treatment ( Figure 5) . We, therefore, investigated the status of AKT phosphorylation in BITC-treated cells because PI3K to AKT to mTOR (PI3K-Akt-mTOR) signaling promotes survival in various cancer cells and mTOR inhibition induces the activation of AKT (39) . In a time course study with lysates from BITC-treated Rv1 cells, the phospho-AKT level was reduced at 24-72 h compared with the 0 h control ( Figure 6A and C) . The protein levels of Bcl-2 in Rv1 cells exhibited decreasing trends, whereas active caspase 3 increased during BITC treatment, which was in agreement with the progression of apoptosis. In PC3 cells, increased levels of phospho-AKT (Ser473) were observed upon BITC exposure (Figure 6B and  D) . The expression of Bcl-2 in BITC-treated PC3 cells was decreased at 6-12 h and started to increase from 24-72 h. The expression of active caspase 3 was detected at 24 h of BITC-treated PC3 cells and decreased at 48-72 h. These data indicate that the activation of AKT signaling and antiapoptotic Bcl-2 upon BITC treatment only occurs in PC3 cells.
Discussion
This study provides the first experimental evidence of autophagy induction in human prostate cancer cells treated with BITC. BITCmediated autophagy in Rv1 and PC3 cells was characterized by the induction of LC3-II followed by the recruitment of processed LC3-II to autophagosomes and the formation of AVOs. Inhibition of autophagy using specific inhibitors, 3-MA, increased apoptosis and failed to rescue the cell death caused by BITC treatment, suggesting that BITC triggers protective autophagy in human prostate cancer cells.
Autophagy is an important cellular defense mechanism in normal development (40) . In prostate cancer cells, several ITCs, such as sulforaphane (31) and phenethyl isothiocyanate (41) , were reported to induce not only apoptosis but also autophagy. A recent study also demonstrated that BITC induces mitochondria-dependent apoptosis in DU145 prostate cancer cells (42) , but whether BITC induces autophagy in DU145 was not investigated. Because the induction of autophagy is considered a defense mechanism against sulforaphaneinduced apoptosis in prostate cancer cells (31) , elucidation of BITCinduced autophagy in prostate cancer cells may provide useful information on this dietary chemopreventive agent and benefit its future application.
In previous studies, BITC showed cytotoxic effects in several cultured cell lines (16) (17) (18) (19) (20) (21) (22) (23) . Our data demonstrated that treatment with BITC affected cell viability and induced apoptosis in Rv1 and PC3 cells (Figure 1 ). BITC-induced autophagy resulted in the formation of LC3-II in Rv1 and PC3 cells (Figure 2A and B) , suggesting that the signaling context, which activates the autophagic flux, was not related to the androgen sensitivity of the prostate cancer cells. Aggregation of LC3 was observed in cells treated with BITC ( Figure 2C and D) . We then detected AVOs formation using To explore the role of autophagy induced by BITC, we investigated the level of cell apoptosis by measuring the percentage of the subdiploid population and caspase 3/7 activity in BITC-treated cells in the absence or presence of the autophagy inhibitor, 3-MA. 3-MA is widely used as an autophagy inhibitor; however, a recent study demonstrated that 3-MA promotes autophagy with prolonged treatment under nutrient-rich conditions, whereas it is capable of suppressing starvation-induced autophagy (43) . In our previous study (30) , inhibition of LC3-II formation was achieved when 1 mM 3-MA was administered to prostate cancer cells treated with 100 µM ZA. We started with the same concentration of 3-MA to inhibit autophagy in BITC-treated cells, but we detected no LC3-II formation in cells treated with 1 mM 3-MA ( Figure 3A and B) . The results showed an increase in the percentage of sub-G 0 /G 1 cells and caspase 3/7 activity with cotreatment of BITC and 3-MA compared with BITC alone (Figure 3 ). These data indicate that autophagy represents a defensive mechanism against BITC-induced apoptosis in human prostate cancer cells.
Cell rescue experiments in which Rv1 and PC3 cells were cotreated with either autophagy or apoptosis inhibitors with BITC showed consistent trends (Figure 4) . Supplementation of an autophagy inhibitor (3-MA) decreased, whereas administration of a broad-spectrum caspase inhibitor (Z-VAD-FMK) restored cell viability compared with cells treated with BITC alone. It is obvious that the caspase inhibitor showed a superior protective effect on BITC-treated cells compared with the autophagy inhibitor. Our results from cell rescue experiment suggest that apoptosis is the main pathway in BITC-induced cell death. mTOR is considered a key regulator in autophagy induction and serves as a defensive mechanism in cells under starvation or stress (35) . Therefore, we examined the mTOR activity in BITC-treated cells. The mTOR activity was decreased in both Rv1 and PC3 cells in a concentration-dependent manner ( Figure 5A and B) . The expression of phospho-mTOR (Ser 2481) was decreased in BITC-treated Rv1 and PC3 cells at 24-72 h. The expression of phospho-ULK1 (Ser757) was decreased in BITC-treated Rv1 cells. However, the expression of phospho-mTOR (2448) and phospho-ULK1 (Ser757) was increased in PC3 cells at later stages of BITC treatment ( Figure 5C-F) . Phosphorylation of ULK1 at Ser757 by mTOR under nutrient sufficiency has been reported (37); however, we did not observe a correlated expression of phospho-mTOR (Ser2481) with phospho-ULK1 (Ser757) in BITC-treated cells. It is possible that other unknown pathway affected by BITC may interfere with the activation of ULK1 and need further investigation. Activation of ERK 1/2 has been shown to stimulate autophagy (44,45), we did not observe ERK 1/2 activation in BITC-treated cells ( Figure 5A and B). These data suggest that BITC-induced autophagy occurs through mTOR inhibition.
We noticed that BITC exhibited superior cytotoxicity in Rv1 cells compared with PC3 cells, and the inhibition of mTOR in PC3 cells was reduced at later stages of BITC treatment. PI3K-AktmTOR is well known as a cancer survival pathway, and a recent study demonstrated that inhibition of mTOR in DU145 cells causes activation of AKT kinase (39) . We, therefore, investigated the status of AKT phosphorylation in a time course study. The results indicated decreased and increased p-AKT in Rv1 and PC3 cells, respectively, upon exposure to BITC (Figure 6 ). The expression level of the Bcl-2 and active caspase 3 proteins showed an increasing and decreasing trend, respectively, in Rv1 cells, which was consistent with apoptosis that detected by the increment of sub-G 0 /G 1 cells Fig. 6 . An increased level of phospho-AKT was detected in BITC-treated PC3 cells. The expression level of total AKT, phospho-AKT (p-AKT, Ser473), Bcl-2, pro-and active-caspase 3 was determined by western blot analysis in Rv1 (A) and PC3 (B) cells upon BITC treatment for the indicated duration. β-actin served as an internal control. The relative expression level of p-AKT (Ser473), Bcl-2 and active caspase 3 was quantitated by densitometric scanning and is presented as the percentages compared with 0 h control in (C) and (D) for Rv1 and PC3 cells, respectively (except for the active caspase 3 from PC3 cells in which the bands were undetectable (ND, not detectable) from 0, 6 and 12 h lysates). The statistical calculation from blots of three independent experiments is shown. The results are presented as the means ± SD; *P < 0.05. (Figure 1) . In PC3 cells, the level of Bcl-2 increased at 24-72 h of BITC treatment, which also correlated with the decreased level of active caspase 3. Inhibition of mTOR was demonstrated to increase upstream receptor tyrosine kinase signaling and activate AKT in metastatic prostate cancer cells (39) . The activation of AKT in later stages of BITC-treated PC3 cells may, therefore, represent a defensive mechanism of advanced prostate cancer cells upon anticancer drug treatment. However, further investigation using a specific inhibitor of AKT activation is needed to elucidate the relationship between AKT activation and BITC resistance in PC3 cells.
In conclusion, this study showed that BITC has anticancer activity in human prostate cancer cells through the induction of apoptotic cell death. BITC also induces early protective autophagy pathways by inhibiting mTOR signaling in these cells regardless of their androgen sensitivity. However, the hormone-refractory PC3 cells showed greater resistance to BITC treatment, which was related to the onset activation of AKT. These data provide basic mechanisms for the chemotherapeutic properties of BITC in prostate cancer cells and show that advanced prostate cancer may induce prosurvival signals to evade BITC treatment.
Supplementary material
Supplementary 
